AWM
SLNO

Avior Wealth Management’s Soleno Therapeutics SLNO Stock Holding History

Avior Wealth Management’s Portfolio SLNO Stock Details SLNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-4,601
Closed -$385K – 731
2025
Q2 		$385K Buy
4,601
+1,191
+35% +$89.1K 0.01% 504
2025
Q1 		$244K Buy
3,410
+1,437
+73% +$70K 0.01% 603
2024
Q4 		$88.7K Buy
+1,973
New +$102K ﹤0.01% 942

Other funds holding SLNO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Avior Wealth Management's SLNO Position: Q3 2025 in Review

Avior Wealth Management sold out of Soleno Therapeutics (SLNO) in Q3 2025, closing a stake of 4,601 shares — an estimated $385K sold.

Avior Wealth Management first reported a position in SLNO in Q4 2024 and held it in 3 quarters. The position peaked at $385K in Q2 2025. 240 funds tracked by Wall St. Rank hold SLNO as of Q3 2025.

  • Avior Wealth Management reported no remaining Soleno Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Avior Wealth Management sold 4,601 Soleno Therapeutics shares in Q3 2025, an estimated $385K.
  • Avior Wealth Management first reported a position in Soleno Therapeutics in Q4 2024 and held it in 3 quarters.
  • Avior Wealth Management's Soleno Therapeutics position peaked at $385K in Q2 2025.
  • 240 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q3 2025.

Based on Avior Wealth Management's 13F filing for Q3 2025, filed 14 Nov 2025.